Candesartan (Atacand)
candesartan cilexetil
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Hypertension | Adults | Monotherapy or combination | FDA Approved |
| Hypertension | Children 1 to <17 years | Monotherapy or combination | FDA Approved |
| Heart failure (NYHA class II–IV) | Adults with LVEF ≤40% | Adjunctive to standard therapy | FDA Approved |
Candesartan is a widely used angiotensin II receptor blocker indicated for blood pressure reduction in adults and paediatric patients aged one year and older. Lowering blood pressure with candesartan reduces the risk of fatal and non-fatal cardiovascular events, primarily stroke and myocardial infarction. In heart failure, the CHARM programme demonstrated that candesartan reduces cardiovascular death and heart failure hospitalisations when added to standard therapy, including ACE inhibitors and beta-blockers.
Migraine prophylaxis (8–16 mg once daily): Supported by two randomised controlled trials and a large phase 2 trial (Lancet Neurol 2025), demonstrating comparable efficacy to propranolol in reducing migraine days. Recognised in several European headache guidelines. Evidence quality: Moderate.
Diabetic nephropathy / microalbuminuria reduction: ARBs as a class are used to reduce proteinuria in patients with type 2 diabetes and hypertension; candesartan has been studied in several trials for this purpose. Evidence quality: Moderate.
Dosing
Adult Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Hypertension — initial monotherapy | 16 mg once daily | 8–32 mg/day | 32 mg/day | Can be given once daily or split BID. Most BP effect seen within 2 weeks; full effect at 4–6 weeks at a given dose. May administer with or without food |
| Hypertension — volume-depleted or diuretic-treated patient | 8 mg once daily | 8–32 mg/day | 32 mg/day | Correct volume depletion before initiating if possible; start lower to avoid symptomatic hypotension |
| Heart failure — NYHA class II–IV (LV systolic dysfunction) | 4 mg once daily | Target 32 mg once daily | 32 mg/day | Double dose every 2 weeks as tolerated toward target of 32 mg once daily. Monitor BP, potassium, and creatinine at each titration step Can be used alone or added to ACE inhibitor (FDA PI) |
| Migraine prophylaxis (off-label) | 8 mg once daily | 8–16 mg once daily | 16 mg/day | Allow 8–12 weeks for effect assessment; may titrate to 16 mg if inadequate response at 4 weeks |
Paediatric Dosing (Hypertension Only)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Children 1 to <6 years | 0.20 mg/kg/day | 0.05–0.4 mg/kg/day | 0.4 mg/kg/day | Oral suspension available (1 mg/mL); give in 1–2 divided doses |
| Children 6 to <17 years (<50 kg) | 4–8 mg/day | 2–16 mg/day | 16 mg/day | Give in 1–2 divided doses |
| Children 6 to <17 years (≥50 kg) | 8–16 mg/day | 4–32 mg/day | 32 mg/day | Give in 1–2 divided doses |
In the CHARM programme, the target dose was 32 mg once daily, and clinical benefit was dose-dependent. Aim for the highest tolerated dose rather than settling at a low dose. In clinical practice, the most common barriers to up-titration are hypotension, rising creatinine, and hyperkalaemia; monitor closely at each doubling step.
Pharmacology
Mechanism of Action
Candesartan cilexetil is an orally active prodrug that is rapidly and completely hydrolysed by esterases in the gastrointestinal wall during absorption to release candesartan, the active moiety. Candesartan binds selectively and with high affinity to the angiotensin II type 1 (AT1) receptor in an insurmountable (non-competitive) fashion, meaning its blockade persists even in the presence of rising angiotensin II levels. By preventing AT1 receptor activation, candesartan inhibits angiotensin II–mediated vasoconstriction, aldosterone secretion, sympathetic nervous system activation, and sodium reabsorption. The AT2 receptor, which may mediate vasodilatory and antiproliferative effects, remains unblocked, potentially contributing to additional cardiovascular benefits. Candesartan does not inhibit ACE (kininase II), so it does not promote bradykinin accumulation — explaining the lower incidence of dry cough compared with ACE inhibitors.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Absolute bioavailability ~15%; Tmax 3–4 h; food does not affect bioavailability | Can be taken regardless of meals; low bioavailability due to incomplete absorption of the prodrug, not first-pass metabolism |
| Distribution | Vd 0.13 L/kg; protein binding >99%; does not cross the blood–brain barrier significantly | Highly protein-bound: unlikely to be displaced by other drugs at therapeutic concentrations; low Vd reflects confinement to plasma compartment |
| Metabolism | Minor hepatic O-deethylation via CYP2C9 to inactive metabolite CV-15959; prodrug hydrolysis is non-CYP | Low CYP interaction potential; hepatic impairment increases exposure (AUC +30% mild, +145% moderate) |
| Elimination | t½ ~9 h; ~67% faeces (via bile), ~33% urine; predominantly excreted unchanged; not removed by haemodialysis | Once-daily dosing adequate for 24-hour coverage; dual elimination pathway means renal impairment alone has moderate impact on clearance |
Side Effects
The overall adverse event profile of candesartan in hypertension trials was comparable to placebo. Data below are from placebo-controlled hypertension trials (candesartan n=2,350; placebo n=1,027) and the CHARM heart failure programme (candesartan n=3,803; placebo n=3,796) per the FDA prescribing information.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Hypotension | 18.8% (vs 9.8% placebo) | In CHARM HF population; dose-related, usually at initiation or titration; more common in patients on high-dose diuretics or combined RAS blockade |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Upper respiratory tract infection | 6% (vs 4% placebo) | Most frequent event in hypertension trials; generally mild and self-limiting |
| Dizziness | 4% (vs 3% placebo) | May be related to blood pressure reduction; advise caution when driving initially |
| Back pain | 3% (vs 2% placebo) | Mechanism unclear; not dose-dependent |
| Pharyngitis | 2% (vs 1% placebo) | Mild; no specific management required |
| Rhinitis | 2% (vs 1% placebo) | Self-limiting; typically does not warrant discontinuation |
| Headache | ~3% (similar to placebo) | Not clearly above placebo in most analyses; led to withdrawal in only 0.6% of patients |
| Hyperkalaemia (HF population) | 9.5% (vs 3.5% placebo) | In CHARM programme (patients on ACE inhibitors); monitor potassium regularly, especially with concomitant potassium-sparing agents |
| Increased serum creatinine (HF population) | 7.1% (vs 3.5% placebo) | Led to study drug discontinuation in the CHARM trials; expected pharmacological effect of RAS blockade in pre-renal states |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Fetal toxicity | Class effect | 2nd/3rd trimester exposure | Discontinue immediately upon detection of pregnancy; fetal monitoring |
| Angioedema | Rare | Any time during treatment | Discontinue permanently; emergency airway management if laryngeal involvement |
| Rhabdomyolysis | Very rare (post-marketing) | Variable | Discontinue; aggressive IV hydration; monitor CK and renal function |
| Acute renal failure | Uncommon | Days to weeks, especially in volume-depleted patients | Hold drug; fluid resuscitation; reassess need for RAS blockade after renal function recovers |
| Severe hyperkalaemia (>6.0 mEq/L) | Uncommon (<1% in HTN; higher in HF) | Weeks, especially with dual RAS blockade or renal impairment | Discontinue or reduce dose; correct potassium; assess concomitant medications; ECG monitoring |
| Severe hypotension (symptomatic) | Uncommon in HTN; 4.2% discontinuation in HF | First dose or early titration | Supine positioning; IV fluids; consider dose reduction or temporary withholding |
| Hepatic transaminase elevation | Rare | Variable | Monitor LFTs; withdraw drug if elevations persist or worsen (5 patients withdrawn in clinical trials) |
| Reason for Discontinuation | Incidence (HF) | Context |
|---|---|---|
| Increased creatinine | 7.1% vs 3.5% placebo | Expected pharmacological effect; often manageable with dose reduction and diuretic adjustment |
| Hypotension | 4.2% vs 2.1% placebo | More common in volume-depleted patients or those on high-dose diuretics |
| Hyperkalaemia | 2.8% vs 0.5% placebo | Risk amplified by concurrent ACE inhibitor, aldosterone antagonist, or impaired renal function |
In heart failure patients co-prescribed ACE inhibitors and/or aldosterone antagonists, potassium rises are common and expected. Before discontinuing candesartan, consider reducing or stopping potassium supplements and potassium-sparing diuretics, checking for dietary sources, and correcting dehydration. A modest rise in creatinine (up to 30% above baseline) may be tolerable if stable; serial monitoring is essential.
Drug Interactions
Candesartan undergoes only minor CYP2C9-mediated metabolism, and no clinically significant pharmacokinetic drug–drug interactions have been identified with commonly co-prescribed agents. The key interactions are pharmacodynamic, centring on dual RAS blockade, potassium homeostasis, and lithium clearance.
Monitoring
-
Blood Pressure
Each visit; 2–4 weeks after dose change
Routine Assess seated and standing BP at initiation. In heart failure, check for symptomatic hypotension at each titration step. Target per current guidelines (AHA/ACC 2025: <130/80 mmHg for most adults). -
Serum Potassium
Baseline; 1–2 weeks after initiation and each dose increase; then periodically
Routine Essential when co-prescribed with ACE inhibitors, aldosterone antagonists, or potassium supplements. Reduce or stop potassium-sparing agents before escalating dose if K+ trends above 5.5 mEq/L. -
Renal Function
Baseline; 1–2 weeks after initiation and each dose increase; then every 3–6 months
Routine Serum creatinine and eGFR. A rise of up to 30% in creatinine may be tolerated if stable. Worsening renal function in paediatric patients (1 in 93 children aged 1–6; 3 in 240 aged 6–17) was observed in clinical trials. -
Haemoglobin / Haematocrit
Baseline; then as clinically indicated
Trigger-based Mean haematocrit decrease of ~1.6% reported versus 0.9% with placebo. Check if anaemia symptoms develop. -
Hepatic Function
If symptoms of liver injury develop
Trigger-based Five patients were withdrawn from clinical trials due to elevated transaminases. Check ALT/AST if jaundice, nausea, or unexplained fatigue occurs. -
Pregnancy Status
Before initiation and as applicable
Routine Confirm negative pregnancy test in women of childbearing potential before starting. Discontinue as soon as pregnancy is detected (FDA boxed warning).
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to candesartan cilexetil or any excipient
- Pregnancy (2nd and 3rd trimesters — FDA boxed warning; avoid throughout pregnancy when possible)
- Children <1 year of age — drugs acting on the RAS can impair normal renal development
- Co-administration with aliskiren in patients with diabetes mellitus
Relative Contraindications (Specialist Input Recommended)
- Bilateral renal artery stenosis or stenosis of a solitary kidney — risk of acute renal failure; ARBs should generally be avoided
- Severe hepatic impairment (Child–Pugh C) — pharmacokinetics not studied; use with extreme caution
- Severe renal impairment (CrCl <30 mL/min) — increased drug exposure and higher risk of hyperkalaemia; maximum 8 mg/day may be appropriate per PK data
- Concomitant dual RAS blockade (ACE inhibitor + ARB) for indications other than specific heart failure protocols — increased risk of adverse outcomes (ONTARGET)
Use with Caution
- Volume or salt depletion — correct before initiating; consider lower starting dose
- Elderly patients — higher Cmax (~50%) and AUC (~80%) observed; start at usual dose but titrate carefully
- Patients of Black race — may have reduced antihypertensive response as a low-renin population; consider combination therapy
- Aortic or mitral valve stenosis / hypertrophic cardiomyopathy — caution with vasodilators
Drugs that act directly on the renin–angiotensin system can cause injury and death to the developing fetus when used during the second and third trimesters. Reported fetal complications include oligohydramnios, skull hypoplasia, lung hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, candesartan should be discontinued as soon as possible.
Patient Counselling
Purpose of Therapy
Candesartan helps protect the heart and blood vessels by blocking the effects of a hormone called angiotensin II that raises blood pressure and strains the heart. In hypertension, lowering blood pressure reduces the long-term risk of stroke and heart attack. In heart failure, candesartan has been shown to reduce the need for hospital admissions and improve survival.
How to Take
Take candesartan once daily (or as directed), at the same time each day, with or without food. Swallow the tablet whole with water. If using the oral suspension for a child, shake well before each dose. Do not stop taking candesartan without consulting a prescriber, even if you feel well, as high blood pressure often has no symptoms.
Sources
- Atacand (candesartan cilexetil) tablets — FDA-approved prescribing information. ANI Pharmaceuticals, Inc. Revised 2020. FDA Label Primary regulatory source for all approved indications, dosing, contraindications, and adverse event rates cited in this monograph.
- Candesartan cilexetil tablets — DailyMed prescribing information. U.S. National Library of Medicine. DailyMed Current DailyMed listing providing updated labelling information including paediatric dosing and oral suspension preparation.
- Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759–766. DOI Overall CHARM analysis demonstrating the broad benefit of candesartan across the spectrum of heart failure, including the 9% reduction in all-cause mortality.
- McMurray JJV, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking ACE inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767–771. DOI Demonstrated 15% relative risk reduction in CV death or HF hospitalisation when candesartan was added to ACE inhibitors.
- Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to ACE inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772–776. DOI Key evidence supporting candesartan as first-line RAS blockade in heart failure patients who cannot tolerate ACE inhibitors.
- Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–781. DOI Evaluated candesartan in HFpEF; showed trend toward benefit and significant reduction in heart failure hospitalisations.
- Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction. Circulation. 2004;110(17):2618–2626. DOI Pooled CHARM low-LVEF analysis confirming an 18% reduction in combined CV death or HF hospitalisation and 12% reduction in all-cause mortality.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263–e421. DOI Current US heart failure guideline positioning ARBs including candesartan in patients intolerant to ACEi/ARNI.
- Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2025;86(18):1567–1678. PubMed Most current US hypertension guideline; includes ARBs as first-line agents for blood pressure control.
- Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289(1):65–69. DOI First RCT demonstrating candesartan 16 mg reduces migraine days compared to placebo.
- Stovner LJ, Linde M, Gravdahl GB, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis. Cephalalgia. 2014;34(7):523–532. DOI Confirmed candesartan is non-inferior to propranolol for migraine prevention with a different side-effect profile.
- Øie LR, Wergeland T, Salvesen Ø, et al. Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2025;24(10):817–827. DOI Largest multicentre trial to date (n=457); both 8 mg and 16 mg reduced monthly migraine days versus placebo.
- Hubner R, Hogemann AM, Sunzel M, Riddell JG. Clinical pharmacokinetics of candesartan. Clin Pharmacokinet. 2002;41(1):7–17. DOI Definitive PK review establishing bioavailability, volume of distribution, protein binding, and half-life parameters used in this monograph.
- Kassem M, Bhatt HM, Gala T, et al. Population pharmacokinetics of candesartan in patients with chronic heart failure. Clin Transl Sci. 2021;14(3):1012–1021. DOI Pop-PK study identifying weight, eGFR, and diabetes as significant covariates affecting candesartan clearance in heart failure patients.